The lighting products of multinational giants entered China from the beginning of the 21st century. The four people (RABS) entered China at different rhythms. In 2003, Siemens first entered the Chinese market. Then Beckman, Abbott and other enterprises came to the fore. In 2006, Roche's electrochemiluminescence entered China. Imported brands are rapidly expanding their territory.
Note: The above data is based on the CFDA registration certificate.
In 2003-2013, in just 10 years, the market capacity of chemiluminescence reached 10 billion. With the gradual enrichment and development of detectable projects, the lighting market is still expanding at a rate of doubling in two years. Chemiluminescence maintains the top three growth rates in the global in vitro diagnostic subdivision. From the perspective of geographic region, China is the fastest growing market, with a compound growth rate of 30% in 2011-2016, which can be reported in the annual report of RABS. It is seen that the Chinese region has become the fastest growing market in the region of growth and will continue to be in rapid development in the next three years.
Due to the multi-brand parallel phenomenon of chemiluminescence, all major brands can maintain a high growth rate. During the period of 2011-2016, imported brands maintained a compound growth rate of more than 25%, and will maintain an average growth rate of 20-15% in the next three years.
Roche's comprehensive strength is strong, and it is the top spot in IVD.
Roche was founded in Switzerland in 1896. In 2015, Roche was 47.5 billion US dollars worldwide, with 78% of medicines and 22% of diagnoses. Roche's excellent products and active sales strategy have made his product lines perform very well, and his comprehensive strength ranks first in the world in in vitro diagnostics.
In the field of immunization, Roche uses electrochemiluminescence as its core product. This product was developed by Baollingman in 1996 and has core patent protection. It is called the fourth generation of chemiluminescence. After Roche acquired the Bollinger Company in 1997, the products were continuously upgraded. Currently, the E170 of 170 T/H and the E411 of 86T/H are the main products. In 2016, Roche Electrochemiluminescence patents officially expired.
At present, there are 105 Roche chemiluminescence projects, covering a wide range of projects, including thyroid function, hormones, allergies, Down syndrome, diabetes, anemia, pre-eclampsia, tumor markers, myocardial markers, concentrated toxemia, transplant drugs. 15 categories of menus, infectious diseases, infectious diseases, bone markers and autoimmunity.
Brown Anti-Slip Gloves,Anti-Slip Pvc Coated Gloves,Rough Sandy Pvc Glove,Super Wear Resistant Glove
JINAN SHANDE SECURITY TECHNOLOGY CO., LTD , https://www.sdsxlb.com